Company Profile

CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE885.20-17.8 (-1.97 % )
PREV CLOSE (Rs.) 903.00
OPEN PRICE (Rs.) 928.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 645614
TODAY'S LOW / HIGH (Rs.)878.25 932.40
52 WK LOW / HIGH (Rs.)565.9 940
NSE885.20 -17.2 (-1.91 % )
PREV CLOSE(Rs.) 902.40
OPEN PRICE (Rs.) 921.95
BID PRICE (QTY) 885.20 (5375 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 11667200
TODAY'S LOW / HIGH(Rs.) 878.30 932.60
52 WK LOW / HIGH (Rs.)565.6 940

Company News

Date Heading Details
13-Apr-2021 Cipla doubles Remdesivir production to meet 'unprecedented' demand <p align="justify">Cipla has doubled production of COVID-19 medication remdesivir to help meet ‘unprecedented demand' as the country battles a massive second wave of infections. India has overtaken Brazil as the world's second-worst coronavirus-hit country after the United States, having administered about 107 million vaccine doses among a population of 1.4 billion.<p align="justify">Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.</p>
01-Apr-2021 Announcement under Regulation 30 (LODR)-Updates on Acquisition We would like to inform you that DigiHealth Technologies LLP, the wholly owned entity of our Indian investee entity i.e. ABCD Technologies LLP (to be renamed as IndoHealth Services LLP), has agreed to acquire 100% ownership interest in Pharmarack Technologies Private Limited in tranches. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFO/CMD/4/2015 dated 9th September, 2015 are given in Annexure 1 to the letter.
01-Apr-2021 Announcement under Regulation 30 (LODR)-Updates on Acquisition We would like to inform you that DigiHealth Technologies LLP, the wholly owned entity of our Indian investee entity i.e. ABCD Technologies LLP (to be renamed as IndoHealth Services LLP), has agreed to acquire 100% ownership interest in Pharmarack Technologies Private Limited in tranches. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFO/CMD/4/2015 dated 9th September, 2015 are given in Annexure 1 to the letter.
31-Mar-2021 Announcement under Regulation 30 (LODR)-Updates on Acquisition We would like to inform you that our investee entity i.e. ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) has through its wholly-owned entity DigiHealth Technologies LLP, acquired 66.02% ownership interest in AIOCD Pharmasofttech Awacs Private Limited ('AWACS') through a combination of (i) direct purchase of 50% ownership interest in AWACS and (ii) indirect purchase of 16.02% ownership interest in AWACS through acquisition of 32.04% shareholding interest in Trikaal Mediinfotech Private Limited. It is also agreed to acquire the balance stake subject to fulfilment of certain terms and conditions. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFO/CMD/4/2015 dated 9th September, 2015 are given in Annexure - 1 to the letter.
31-Mar-2021 Announcement under Regulation 30 (LODR)-Updates on Acquisition We would like to inform you that our investee entity i.e. ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) has through its wholly-owned entity DigiHealth Technologies LLP, acquired 66.02% ownership interest in AIOCD Pharmasofttech Awacs Private Limited ('AWACS') through a combination of (i) direct purchase of 50% ownership interest in AWACS and (ii) indirect purchase of 16.02% ownership interest in AWACS through acquisition of 32.04% shareholding interest in Trikaal Mediinfotech Private Limited. It is also agreed to acquire the balance stake subject to fulfilment of certain terms and conditions. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFO/CMD/4/2015 dated 9th September, 2015 are given in Annexure - 1 to the letter.
31-Mar-2021 Cipla enters into agreement to become partner in ABCD Technologies LLP <P align=justify>Cipla has entered into an agreement to become a partner in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP). The target entity is a recently incorporated limited liability partnership (LLP) and is yet to commence business activities.<P align=justify>Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.<BR>
31-Mar-2021 Cipla moves up on entering into agreement to become partner in ABCD Technologies LLP <P align=justify>Cipla is currently trading at Rs. 818.95, up by 6.50 points or 0.80% from its previous closing of Rs. 812.45 on the BSE.<BR><P align=justify>The scrip opened at Rs. 812.20 and has touched a high and low of Rs. 823.65 and Rs. 805.30 respectively. So far 118770 shares were traded on the counter.<BR><P align=justify>The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 878.55 on 03-Feb-2021 and a 52 week low of Rs. 410.60 on 01-Apr-2020.<BR><P align=justify>Last one week high and low of the scrip stood at Rs. 823.65 and Rs. 781.50 respectively. The current market cap of the company is Rs. 66303.38 crore.<BR><P align=justify>The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 40.05% and 23.25% respectively.<P align=justify>Cipla has entered into an agreement to become a partner in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP). The target entity is a recently incorporated limited liability partnership (LLP) and is yet to commence business activities.<P align=justify>Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.<BR>
24-Mar-2021 Announcement under Regulation 30 (LODR)-Press Release / Media Release Press Release - Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats
23-Mar-2021 Intimation Of Re-Appointment Of Managing Director In compliance with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that based on the recommendation of Nomination and Remuneration Committee and subject to approval of the shareholders, and any required regulatory approvals and applicable conditions thereof, the Board of Directors, at its meeting held on 23rd March, 2021, has considered and approved the re-appointment of Mr. Umang Vohra (DIN: 02296740), Managing Director, designated as 'Managing Director and Global Chief Executive Officer' of the Company, for a further period of five (5) years w.e.f. 1st April, 2021 to 31st March, 2026 (both days inclusive).
23-Mar-2021 Cipla inches up as its affiliate enters into strategic partnership with SIGA Technologies <p align="justify">Cipla is currently trading at Rs. 777.80, up by 5.00 points or 0.65% from its previous closing of Rs. 772.80 on the BSE.</p><p align="justify">The scrip opened at Rs. 779.00 and has touched a high and low of Rs. 779.00 and Rs. 773.00 respectively. So far 7905 shares were traded on the counter.</p><p align="justify">The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 878.55 on 03-Feb-2021 and a 52 week low of Rs. 371.65 on 23-Mar-2020.</p><p align="justify">Last one week high and low of the scrip stood at Rs. 795.60 and Rs. 738.25 respectively. The current market cap of the company is Rs. 62323.26 crore.</p><p align="justify">The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 40.05% and 23.25% respectively.</p><p align="justify">Cipla Therapeutics, a division of Cipla USA, Inc., an affiliate of Cipla and SIGA Technologies, Inc. (SIGA) have entered into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats. The strategic collaboration between Cipla and SIGA will provide the Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services (HHS) department, with solutions for its biothreat and public health needs.</p><p align="justify">The World Health Organization has declared that anti-microbial resistance (AMR) one of the top 10 global public health threats facing humanity 2 which puts at risk the effective prevention and treatment of a wide range of infections. According to the AMR Industry Alliance, a global AMR private sector coalition, AMR is the ability of a microorganism (such as bacteria, viruses, and some parasites) to stop an antimicrobial (such as antibiotics, antivirals and antimalarials) from working against it. It is an increasingly significant threat to global public health which is present in every country around the world and infections caused by drug-resistant bacteria can cause death.</p><p align="justify">Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.<br></p>